rgp120/HIV-1IIIB
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc.
Conditions
HIV Infections
Phase 1
A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)
CompletedNCT00001021
Target: 57Updated: 2005-06-24
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
CompletedNCT00000779
End: 1996-09-30Target: 130Updated: 2021-11-04
A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)
CompletedNCT00001020
End: 1995-02-28Target: 28Updated: 2012-05-18
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
CompletedNCT00001026
End: 1994-12-31Target: 56Updated: 2021-11-04
A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
CompletedNCT00001992
Updated: 2005-06-24